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Background
Evidence-based risk factors associated with
Clostridium difficile infectious diarrhea have been
identified through systematic review of the
literature. Factors identified include increasing
age, increased severity of underlying diseases,
non-surgical gastrointestinal procedures, presence
of a nasogastric tube, stays in intensive care units,
increasing duration of hospital stay, increased
duration of antibiotic treatment, and multiple
antibiotic administration.1
C. difficile is associated with significant
morbidity, mortality, increased length of hospital
stay, and increased cost. Its incidence doubled
between 2000 and 2002.2 Two recent studies have
identified the use of proton pump inhibitors as an
associated risk factor for C. difficile diarrhea.3,4
Commonly prescribed proton pump inhibitors
include esomeprazole (Nexium), lansoprazole
(Prevacid), omeprazole (Prilosec), pantoprazole
(Protonix), and rabeprazole (Aciphex).
In the current investigation both cohort and
case-controlled studies were undertaken to assess
acid-suppressive therapy as a risk factor for C.
difficile infection.4

Citation
Dial S, Alrasadi K, Manoukian C, et al. Risk
of Clostridium difficile diarrhea in hospital inpatients prescribed proton pump inhibitors: cohort
and case-control studies. CMAJ 2004;171:33-8.

Methods
In the cohort study, 1,187 inpatients who had
received antibiotics over a nine month period
were identified. Patients in this group were
categorized as to whether they received acid
suppressive therapy.
They were further
subdivided by their receipt of either proton pump
inhibitor or H2-blocker therapy.
Hospital

laboratory reports were used to confirm positive
assay results for C. difficile toxin.
The case-control study was performed to
address the possibility that patients receiving
proton pump inhibitors were sicker and had other
risk factors for C. difficile. Cases were defined as
patients with an inpatient history of diarrhea and
positive assay results for C. difficile toxin.
Controls were defined as any inpatient within the
same study time period who received any
antibiotic and had at least a five-day length of stay
with survival at least 30 days past admission.
Controls were also matched to cases by ward, age,
class of antibiotic, and number of antibiotics.
The study end point was to determine the risk of
C. difficile diarrhea in patients receiving proton
pump inhibitors.

Results
C. difficile diarrhea developed in 6.8% of the
cohort patients. Of the patients who received
antibiotics and a proton pump inhibitor 9.3%
developed C. difficile diarrhea. Whereas those
who received antibiotics but no proton pump
inhibitor experienced a 4.4% incidence (RR 2.1,
95% CI 1.4 to 3.4). The relative risk of C.
difficile was higher in patients receiving proton
pump inhibitors compared with H2-blocker
recipients (OR 2.1, 95% CI 1.2 to 3.5 vs. OR 1.1,
95% CI 0.4 to 3.4).
In the case-control study, 94 patients
developed C. difficile diarrhea. The case and
control subjects were similar in age, number and
type of antibiotic, and comorbidity factors. Case
subjects were more likely to be female, have renal
disease, MRSA colonization, and had past
admissions. It was also noted that one patient
receiving a proton pump inhibitor but no
antibiotics, developed C. difficile diarrhea. Of the
cases, 64% were receiving proton pump inhibitors
More. . .
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as compared with 36% of the controls (unadjusted
OR 3.1, 95% CI 1.7 to 5.6).

Author Conclusions
Inpatients receiving proton pump inhibitors
were at greater risk for C. difficile diarrhea.

Commentary
Clostridium difficile is an anaerobic grampositive rod accounting for approximately 15% to
25% of all causes of antibiotic-associated
diarrhea. Some of the clinical signs of infection
include watery diarrhea, fever, abdominal pain
and tenderness, and nausea. It may also cause
pseudomembranous colitis.5
It is most frequently transmitted by the hands
of health care workers who have had contact with
contaminated feces or environmental surfaces.5
Symptomatic patients should be tested for C.
difficile if they are or have recently been
hospitalized and have taken antibiotics or are
receiving antibiotics at home or in a nursing care
facility. Stool culture and toxin assays are
recommended diagnostic tests for C. difficile.5
When C. difficile is confirmed, first-line
antibiotic treatment with oral metronidazole
should be prescribed. The recommended dose is
250 mg four times daily or 500 mg twice daily for
ten to 14 days.6 Intravenous metronidazole may
be effective in those unable to take the drug
orally.7 Oral vancomycin (125 mg four times
daily for ten to 14 days) should be reserved for
those who have failed first-line treatment, are
intolerant to metronidazole, or have metronidazole
contraindications. Intravenous vancomycin is not
excreted into the colon and therefore should not
be used for C. difficile.6
Patients who have C. difficile colonization test
positive but are asymptomatic. These colonized
cases should not be treated with antibiotics since
there is decreased risk for active disease.5
Prevention and control of C. difficile requires
contact precautions for all symptomatic cases
including frequent handwashing, use of gloves,
use of gowns if soiling is possible, and private
room placement. Appropriate medical device and
environmental cleaning with EPA-approved
disinfectants is essential.6
Judicious use of antibiotics is a key
preventative measure. The antibiotics most often
associated with C. difficile diarrhea are

clindamycin,
broad-spectrum
penicillins,
cephalosporins, and in several case reports,
quinolones.8,9
Methotrexate or paclitaxel chemotherapy can
also present risks.8
Several case reports have identified C. difficile
colitis associated with “triple” regimen therapy to
eradicate Helicobacter pylori. The regimens
consisted of clarithromycin, metronidazole, and
omeprazole or clarithromycin, amoxicillin, and
lansoprazole.10-12
Proton pump inhibitors are prescribed for a
variety of indications including duodenal and
gastric ulcer, esophagitis, gastroesophageal reflux
disease, peptic ulcer disease, Zollinger-Ellison
Syndrome, heartburn, prophylaxis of upper
gastrointestinal bleeding associated with nonsteroidal anti-inflammatory agent use, and acute
upper gastrointestinal bleeding. The overuse of
acid-suppressing drugs has been described in
hospitalized patients.13
Inappropriate use
especially as prophylaxis of stress ulcers in lowrisk patients is common.13
The normal pH of the stomach is a host
defense and barrier to ingested pathogens.14
Bacterial overgrowth and colonization with fecal
bacteria have been identified in studies with acidinhibitory therapy.14,15 Acid-suppressing drugs are
associated with bacterial overgrowth in the
stomach and influenza viruses in the gastric
mucosa.14,16
Studies have also shown that
bacterial overgrowth depends on the intensity of
inhibition of gastric acid secretion and
corresponding increase in pH. Proton pump
inhibitors have greater inhibition of gastric acid
secretion
compared
with
H2
receptor
antagonists.15,17
Careful consideration should be taken when
proton pump inhibitors are prescribed for
inpatients when concomitant antibiotics are used.
Prophylactic use of proton pump inhibitors should
be examined for appropriateness given the
findings of this study. Accepted indications for
proton pump inhibitors include treatment of active
gastroesophageal reflux disease (GERD), acute
upper gastrointestinal bleeding, active peptic ulcer
disease, and Zollinger-Ellison Syndrome.18,19
Preliminary evidence suggests that development
of C. difficile infection is a potential consequence
when proton pump inhibitors are combined with
antibiotic therapy in hospitalized patients
More. . .
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[Evidence level B, clinical cohort study, casecontrol study].4
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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Levels of Evidence
In accordance with the trend towards Evidence-Based
Medicine, we are citing the LEVEL OF EVIDENCE
for the statements we publish.
Level
A

B

C
D

Definition
High-quality randomized controlled trial (RCT)
High-quality meta-analysis (quantitative
systematic review)
Nonrandomized clinical trial
Nonquantitative systematic review
Lower quality RCT
Clinical cohort study
Case-control study
Historical control
Epidemiologic study
Consensus
Expert opinion
Anecdotal evidence
In vitro or animal study

Adapted from Siwek J, et al. How to write an evidence-based
clinical review article. Am Fam Physician 2002;65:251-8.
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